These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29338498)

  • 1. From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications.
    Perrotta FM; De Socio A; Scriffignano S; Lubrano E
    Expert Rev Clin Immunol; 2018 Mar; 14(3):207-213. PubMed ID: 29338498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
    Smolen JS; Braun J; Dougados M; Emery P; Fitzgerald O; Helliwell P; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Schoels M; Sieper J; Wit Md; Baraliakos X; Betteridge N; Burgos-Vargas R; Collantes-Estevez E; Deodhar A; Elewaut D; Gossec L; Jongkees M; Maccarone M; Redlich K; van den Bosch F; Wei JC; Winthrop K; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):6-16. PubMed ID: 23749611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
    Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
    Braun J; Kiltz U; Heldmann F; Baraliakos X
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
    Poddubnyy D; Gensler LS
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?
    Kiltz U; Baraliakos X; Braun J; van der Heijde D
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S47-50. PubMed ID: 24129137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.
    Paramarta JE; De Rycke L; Ambarus CA; Tak PP; Baeten D
    Rheumatology (Oxford); 2013 Oct; 52(10):1873-8. PubMed ID: 23861532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriatic arthritis and spondyloarthritis assessment and management update.
    Mease P
    Curr Opin Rheumatol; 2013 May; 25(3):287-96. PubMed ID: 23492739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
    Smolen JS; Schöls M; Braun J; Dougados M; FitzGerald O; Gladman DD; Kavanaugh A; Landewé R; Mease P; Sieper J; Stamm T; Wit M; Aletaha D; Baraliakos X; Betteridge N; Bosch FVD; Coates LC; Emery P; Gensler LS; Gossec L; Helliwell P; Jongkees M; Kvien TK; Inman RD; McInnes IB; Maccarone M; Machado PM; Molto A; Ogdie A; Poddubnyy D; Ritchlin C; Rudwaleit M; Tanew A; Thio B; Veale D; Vlam K; van der Heijde D
    Ann Rheum Dis; 2018 Jan; 77(1):3-17. PubMed ID: 28684559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab: a promising therapeutic option in spondyloarthritis.
    Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
    Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease.
    Song IH; Haibel H; Poddubnyy D; Braun J; Sieper J
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S37-42. PubMed ID: 24129135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different?
    Chandran V
    Curr Opin Rheumatol; 2019 Jul; 31(4):329-334. PubMed ID: 31135567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of low disease activity and remission in psoriatic arthritis.
    Lubrano E; Perrotta FM; Kavanaugh A
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S51-4. PubMed ID: 26470835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
    van der Heijde D; Deodhar A; Fleischmann R; Mease PJ; Rudwaleit M; Nurminen T; Davies O
    Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1030-1039. PubMed ID: 27696727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis.
    Machado PM; Raychaudhuri SP
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):711-28. PubMed ID: 25488780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we reduce the dosage of biologics in spondyloarthritis?
    Olivieri I; D'Angelo S; Padula A; Leccese P; Nigro A; Palazzi C
    Autoimmun Rev; 2013 May; 12(7):691-3. PubMed ID: 22940233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E; Parsons WJ; Perrotta FM
    J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology.
    Wendling D; Dougados M; Berenbaum F; Brocq O; Schaeverbeke T; Mazieres B; Marcelli C; Leparc JM; Bertin P; Robin M; Sibilia J; Lafforgue P; Prati C; Combe B; Gottenberg JE;
    J Rheumatol; 2012 Dec; 39(12):2327-31. PubMed ID: 22896028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.